AbbVie reports second-quarter 2026 financial results
Net revenues rose 10.2% to $16.99 billion, with GAAP diluted EPS of $2.03 and adjusted diluted EPS of $3.65
See the latest news and media coverage for AbbVie. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company
abbvie.comLast updated
In short: AbbVie secured several EU regulatory approvals, completed a $10.9 billion acquisition of Apogee Therapeutics, and reached new stock highs.
Net revenues rose 10.2% to $16.99 billion, with GAAP diluted EPS of $2.03 and adjusted diluted EPS of $3.65
The approval makes RINVOQ the first systemic treatment for non-segmental vitiligo in the EU, based on Phase 3 data.
Approval based on Phase 3 trials showing significant scalp hair regrowth at week 24, for patients 12 and older.
The U.S. primary endpoint was overall survival and was not met; full results will be published.
The company, one of the rare healthcare sector Dividend Kings, wasn't looking too royal on the last trading day of the week.
AbbVie (ABBV) stock dips despite better-than-expected Q2 results as the company lowers 2026 earnings guidance to reflect its $10.9B Apogee deal. Read more here.
AbbVie falls on guidance cut, T. Rowe Price beats EPS, and Moderna drops on vaccine trial failure.
AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee...
Track AbbVie and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to AbbVie and other trending companies.